## EXAS: Exact Sciences Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.6% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0); RSI 82 overbought. Stock is in no-man's land without clear edge. Caution: declining volume (30% of avg), overbought RSI (82).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($99.66)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Exact Sciences Corp.: Turning DNA Into a Weapon Against Cancer**
- Source: AD HOC NEWS | 20251231T130849 | Bullish | Relevance: 100%
- Exact Sciences Corp. is revolutionizing cancer detection through non-invasive, DNA-driven tests like Cologuard and Oncotype. The company focuses on early cancer detection, challenging traditional methods by offering consumer-grade usability paired with rigorous genomics. Its strategy involves continuous innovation, expanding beyond current flagship products into multi-cancer early detection and minimal residual disease monitoring, aiming to solidify its market position against competitors.

**2. Exact Sciences Corp.: How a Diagnostics Powerhouse Is Rewriting the Cancer Playbook**
- Source: AD HOC NEWS | 20251230T110857 | Bullish | Relevance: 100%
- Exact Sciences Corp. is transforming cancer screening into a software-driven diagnostics platform, making early detection more routine. The company is known for its Cologuard at-home colon cancer screening test and has expanded into multi-cancer early detection and precision oncology. Their strategy focuses on noninvasive screening, precision oncology tools like Oncotype DX, and developing multi-cancer early detection (MCED) via a data-driven approach, positioning them as a critical infrastructure in cancer care.

**3. Exact Sciences accelerates executive bonuses and equity awards ahead of merger**
- Source: Investing.com | 20251229T140913 | Neutral | Relevance: 100%
- Exact Sciences Corp. announced that its board has approved accelerated vesting and payment of annual bonuses and equity awards for executive officers. This decision is related to the company's pending merger with Abbott Laboratories and aims to address potential tax implications under Sections 280G and 4999 of the Internal Revenue Code. The move also outlines specific accelerated payments for key executives and details regarding annual bonuses, RSU, and PSU awards, along with clawback provisions.

**4. Smart Oncology: 5 Stocks Chasing the $317B Prize**
- Source: Morningstar | 20251231T120849 | Bullish | Relevance: 100%
- The precision oncology market is rapidly expanding, driven by advancements in biomarker-guided therapies and AI. This article highlights five key players—Oncolytics Biotech Inc., Exact Sciences Corp., Veracyte, Inc., Hologic, Inc., and Personalis, Inc.—that are at the forefront of this $317 billion industry. These companies are developing innovative solutions for cancer diagnosis and treatment, offering new hope for personalized and effective care.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 7 ($1.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- FMR, LLC: 9.8% (-30.6%)
- Vanguard Group Inc: 9.4% (-0.5%)
- Capital World Invest: 8.5% (-11.3%)
- Blackrock Inc.: 5.6% (+0.3%)
- Wellington Managemen: 2.8% (-55.6%)

### Key Risks

1. Volume divergence: price rising (+1.6% MRS) on declining volume (30% of avg) suggests distribution.
2. Overbought RSI (82) with bearish MACD signals exhaustion.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.6% over 5 days suggests accumulation.

### Fundamentals

Forward P/E 90.8x attractive for 231% earnings growth. Balance sheet: strong liquidity (2.7x). Insider selling cluster ($1.7M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.3B |
| Beta | 1.42 |
| 52W Range | $38.81 - $102.66 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.07 |
| Forward P/E | 90.8 |
| Current P/E | 300.4 |
| YoY Growth | 230.6% |
| EPS Direction | FALLING |

### Technicals

MRS_20 strengthening from -1.0% to 0.6% (+1.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.4pp (needs >4.0% for momentum thesis). MRS_5 at 0.8% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.24), momentum weakening. RSI overbought at 82, risk of mean reversion. Volume at 30% of 20MA suggests lack of conviction. OFD pattern: -MUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.64% (CS: 63) | Neutral |
| RSI_14 | 81.5 | Overbought |
| MACD Histogram | -1.24 | Bearish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 1.178x | Above |
| vs SMA200 | 1.702x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $101.56
- **Stop Loss:** $99.66 (1.9% risk)
- **Target:** $103.46 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 757
- **Position Value:** $76,880.92
- **Portfolio %:** 76.88%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with mixed signals requiring caution. VIX at 14.95 suggests calm markets, but record repo borrowing and narrowing breadth (51.4%) indicate stress beneath the surface. Positive yield curve (+62bps) and stable economic data support risk assets, but year-end dynamics mask true liquidity conditions.*

### Earnings

**Next:** 2026-02-25 (Est: $0.08)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.16 | $0.24 | +49.5% |
| 2025Q2 | $0.05 | $0.10 | +84.9% |
| 2025Q1 | $-0.10 | $-0.36 | -276.9% |
| 2024Q4 | $-0.19 | $-0.06 | +67.9% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*